| HOME >> MEDICINE >> TECHNOLOGY |
"This syringe, a result of our partnership with OXO(R), demonstrates UCB's commitment to patients with severe diseases. I am proud of the fact that people living with rheumatoid arthritis worked directly with the design and engineering teams to develop this syringe. We have designed a syringe that that takes into account some of the challenges that come with self-injection. UCB has gone beyond providing a new effective treatment option. Our long-term partnership with OXO(R) will allow us to help make everyday living easier for rheumatoid arthritis patients." said Roch Doliveux, Chief Executive Officer of UCB. "In addition, we are pleased to offer people with Crohn's disease in the U.S. the option of self-administering Cimzia(R) using this newly designed syringe. Cimzia(R) patients will now have the convenience of at-home self-injections," said Doliveux.
"OXO(R) was built on the foundation of Universal Design, which focuses on creating easy and comfortable-to-use products for the widest spectrum of users possible," said Alex Lee, President of OXO(R). "In partnering with UCB, we were able to apply our design principles in a new setting. The result is a prefilled syringe that helps provide comfort and control for a wide variety of patient self-administration abilities and user styles."
The Design Process
The development of UCB's new prefilled syringe was initiated when UCB patient research identified that self-injection was a challenge for many people with RA.
UCB and OXO(R) brought in patients to assess the syringes available in the market place and the UCB prototype. This led to the redesign of many aspects of the syringe and its packaging. Specificall
'/>"/>
| SOURCE UCB Copyright©2009 PR Newswire. All rights reserved |